References:
1. Li Y, Shi J, Xia J, Duan J, Chen L, Yu X, et al. Asymptomatic and
Symptomatic Patients With Non-severe Coronavirus Disease (COVID-19) Have
Similar Clinical Features and Virological Courses: A Retrospective
Single Center Study. Front Microbiol. 2020;11:1570.
2. Climente-Martí M, Ruiz-Millo O, López-Cruz I, Atienza-García Á,
Martínez-Moragón E, Garijo-Gómez E, et al. Impact of intermediate to
high doses of methylprednisolone on mortality rate in patients with
COVID-19 pneumonia-induced severe systemic inflammation. Int J Clin
Pract. 2021 Sep;75(9):e14479.
3. Parasher A. COVID-19: Current understanding of its Pathophysiology,
Clinical presentation and Treatment. Postgrad Med J [Internet].
2021;97(1147):312–20. Available from:
https://pmj.bmj.com/content/97/1147/312
4. Raju R, V P, Biatris PS, J SJUC. Therapeutic role of corticosteroids
in COVID-19: a systematic review of registered clinical trials. Futur J
Pharm Sci. 2021;7(1):67.
5. Alexaki VI, Henneicke H. The Role of Glucocorticoids in the
Management of COVID-19. Horm Metab Res = Horm und Stoffwechselforsch =
Horm Metab. 2021 Jan;53(1):9–15.
6. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al.
Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021
Feb;384(8):693–704.
7. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC,
et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in
Patients With Moderate or Severe Acute Respiratory Distress Syndrome and
COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020
Oct;324(13):1307–16.
8. Munch MW, Myatra SN, Vijayaraghavan BKT, Saseedharan S, Benfield T,
Wahlin RR, et al. Effect of 12 mg vs 6 mg of Dexamethasone on the Number
of Days Alive Without Life Support in Adults With COVID-19 and Severe
Hypoxemia: The COVID STEROID 2 Randomized Trial. JAMA. 2021
Nov;326(18):1807–17.
9. Dequin P-F, Heming N, Meziani F, Plantefève G, Voiriot G, Badié J, et
al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support
Among Critically Ill Patients With COVID-19: A Randomized Clinical
Trial. JAMA. 2020 Oct;324(13):1298–306.
10. Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al.
Effect of Hydrocortisone on Mortality and Organ Support in Patients With
Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized
Clinical Trial. JAMA. 2020 Oct;324(13):1317–29.
11. Tang X, Feng Y-M, Ni J-X, Zhang J-Y, Liu L-M, Hu K, et al. Early Use
of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care
Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind,
Randomized Control Trial. Respiration. 2021;100(2):116–26.
12. Yu L-M, Bafadhel M, Dorward J, Hayward G, Saville BR, Gbinigie O, et
al. Inhaled budesonide for COVID-19 in people at high risk of
complications in the community in the UK (PRINCIPLE): a randomised,
controlled, open-label, adaptive platform trial. Lancet (London,
England). 2021 Sep;398(10303):843–55.
13. Ramakrishnan S, Nicolau DVJ, Langford B, Mahdi M, Jeffers H, Mwasuku
C, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC):
a phase 2, open-label, randomised controlled trial. Lancet Respir Med.
2021 Jul;9(7):763–72.
14. Clemency BM, Varughese R, Gonzalez-Rojas Y, Morse CG, Phipatanakul
W, Koster DJ, et al. Efficacy of Inhaled Ciclesonide for Outpatient
Treatment of Adolescents and Adults With Symptomatic COVID-19: A
Randomized Clinical Trial. JAMA Intern Med. 2022 Jan;182(1):42–9.
15. Ezer N, Belga S, Daneman N, Chan A, Smith BM, Daniels S-A, et al.
Inhaled and intranasal ciclesonide for the treatment of covid-19 in
adult outpatients: CONTAIN phase II randomised controlled trial. BMJ.
2021 Nov;375:e068060.
16. van Paassen J, Vos JS, Hoekstra EM, Neumann KMI, Boot PC, Arbous SM.
Corticosteroid use in COVID-19 patients: a systematic review and
meta-analysis on clinical outcomes. Crit Care. 2020 Dec;24(1):696.
17. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al.
Surviving Sepsis Campaign: Guidelines on the Management of Critically
Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med. 2020
Jun;48(6):e440–69.
18. Russell CD, Millar JE, Baillie JK. Clinical evidence does not
support corticosteroid treatment for 2019-nCoV lung injury. Lancet
(London, England). 2020 Feb;395(10223):473–5.
19. Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al.
Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case
Report and Systematic Review of Literature. Mycopathologia. 2021
May;186(2):289–98.
20. Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi KK, Kale PG, et
al. SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids-An Unholy
Trinity in Invasive Fungal Infections of the Maxillofacial Region? A
Retrospective, Multi-centric Analysis. J Maxillofac Oral Surg. 2021
Sep;20(3):418–25.
21. Chauvet P, Mallat J, Arumadura C, Vangrunderbeek N, Dupre C, Pauquet
P, et al. Risk Factors for Invasive Pulmonary Aspergillosis in
Critically Ill Patients With Coronavirus Disease 2019-Induced Acute
Respiratory Distress Syndrome. Crit care Explor. 2020 Nov;2(11):e0244.
22. Liu J, Wang T, Cai Q, Sun L, Huang D, Zhou G, et al. Longitudinal
changes of liver function and hepatitis B reactivation in COVID-19
patients with pre-existing chronic hepatitis B virus infection. Hepatol
Res. 2020 Nov;50(11):1211–21.
23. Khilnani GC, Hadda V. Corticosteroids and ARDS: A review of
treatment and prevention evidence. Lung India. 2011 Apr;28(2):114–9.
24. Wells K, Littell JH. Study Quality Assessment in Systematic Reviews
of Research on Intervention Effects. Res Soc Work Pract [Internet].
2008 Feb 26;19(1):52–62. Available from:
https://doi.org/10.1177/1049731508317278
25. Tang X, Feng YM, Ni JX, Zhang JY, Liu LM, Hu K, et al. Early Use of
Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care
Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind,
Randomized Control Trial. Respiration [Internet].
2021;100(2):116–26. Available from:
https://pubmed.ncbi.nlm.nih.gov/33486496/
26. Ding C, Feng X, Chen Y, Yuan J, Yi P, Li Y, et al. Effect of
Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in
Patients with Mild COVID-19: A Retrospective Cohort Study. Infect Dis
Ther [Internet]. 2020/09/28. 2020 Dec;9(4):943–52. Available from:
https://pubmed.ncbi.nlm.nih.gov/32986226
27. Yang R, Xiong Y, Ke H, Chen T, Gao S. The role of methylprednisolone
on preventing disease progression for hospitalized patients with severe
COVID-19. Eur J Clin Invest. 2020 Nov;50(11):e13412.
28. Chen Q, Song Y, Wang L, Zhang Y, Han L, Liu J, et al.
Corticosteroids treatment in severe patients with COVID-19: a propensity
score matching study. Expert Rev Respir Med [Internet]. 2021 Apr
3;15(4):543–52. Available from:
https://doi.org/10.1080/17476348.2021.1856659
29. Liu Z, Li X, Fan G, Zhou F, Wang Y, Huang L, et al. Low-to-moderate
dose corticosteroids treatment in hospitalized adults with COVID-19.
Clin Microbiol Infect [Internet]. 2021;27(1):112–7. Available from:
https://doi.org/10.1016/j.cmi.2020.09.045
30. Li Q, Li W, Jin Y, Xu W, Huang C, Li L, et al. Efficacy Evaluation
of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized
with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study. Infect
Dis Ther. 2020 Dec;9(4):823–36.
31. Li Y, Li J, Ke J, Jiao N, Zhu L, Shen L, et al. Adverse Outcomes
Associated With Corticosteroid Use in Critical COVID-19: A Retrospective
Multicenter Cohort Study. Front Med. 2021;8:604263.
32. Liu J, Zhang S, Dong X, Li Z, Xu Q, Feng H, et al. Corticosteroid
treatment in severe COVID-19 patients with acute respiratory distress
syndrome. J Clin Invest. 2020 Dec;130(12):6417–28.
33. Ma Q, Qi D, Deng XY, Yuan GD, Tian WG, Cui Y, et al. Corticosteroid
therapy for patients with severe novel Coronavirus disease 2019. Eur Rev
Med Pharmacol Sci [Internet]. 2020;24(15):8194–201. Available from:
https://pubmed.ncbi.nlm.nih.gov/32767349/
34. You X, Wu C, Fu Y, He ZID, Huang P, Chen G, et al. The use of
methylprednisolone in COVID-19 patients: A propensity score matched
retrospective cohort study. PLoS One [Internet]. 2020; Available
from: https://doi.org/10.1371/journal.pone.0244128
35. Van Den Eynde E, Gasch O, Oliva JC, Prieto E, Calzado S, Gomila A,
et al. Corticosteroids and tocilizumab reduce in-hospital mortality in
severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.
Infect Dis (Auckl) [Internet]. 2021;53(4):291–302. Available from:
https://doi.org/10.1080/23744235.2021.1884286
36. Piniella-Ruiz E, Bellver-Álvarez MT, Mestre-Gómez B,
Escolano-Fernández B, Vinat-Prado S, Cabezas-Olea R, et al. Impact of
Systemic Corticosteroids on Mortality in Older Adults With Critical
COVID-19 Pneumonia. J Gerontol A Biol Sci Med Sci. 2021
Jul;76(8):e127–32.
37. Moreno G, Carbonell R, Martin-Loeches I, Solé-Violán J, Correig I
Fraga E, Gómez J, et al. Corticosteroid treatment and mortality in
mechanically ventilated COVID-19-associated acute respiratory distress
syndrome (ARDS) patients: a multicentre cohort study. Ann Intensive Care
[Internet]. 2021;11:159. Available from:
https://doi.org/10.1186/s13613-021-00951-0
38. Ruiz-Irastorza GID, Pijoan J-I, Bereciartua E, Dunder S, Dominguez
JID, Garcia-Escudero P, et al. Second week methyl-prednisolone pulses
improve prognosis in patients with severe coronavirus disease 2019
pneumonia: An observational comparative study using routine care data.
PLoS One [Internet]. 2020; Available from:
https://doi.org/10.1371/journal.pone.0239401
39. Solanich X, Antolí A, Rocamora-Blanch G, Padullés N, Fanlo-Maresma
M, Iriarte A, et al. Methylprednisolone Pulses Plus Tacrolimus in
Addition to Standard of Care vs. Standard of Care Alone in Patients With
Severe COVID-19. A Randomized Controlled Trial. Front Med
[Internet]. 2021;8:691712. Available from:
file:///pmc/articles/PMC8236585/
40. Ana F-C, Belén R-A, Ana M-G, Aránzazu S-L, Patricia M-S, Adolfo
C-SG, et al. A Retrospective Controlled Cohort Study of the Impact of
Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality. Antimicrob
Agents Chemother [Internet]. 2022 Apr 28;64(9):e01168-20. Available
from: https://doi.org/10.1128/AAC.01168-20
41. Strauss R, Jawhari N, Attaway AH, Hu B, Jehi L, Milinovich A, et al.
Intranasal Corticosteroids Are Associated with Better Outcomes in
Coronavirus Disease 2019. J Allergy Clin Immunol Pract [Internet].
2021;9(11):3934-3940.e9. Available from:
https://doi.org/10.1016/j.jaip.2021.08.007
42. Nelson BC, Laracy J, Shoucri S, Dietz D, Zucker J, Patel N, et al.
Clinical Outcomes Associated With Methylprednisolone in Mechanically
Ventilated Patients With COVID-19. Clin Infect Dis [Internet]. 2021
May 4;72(9):e367–72. Available from:
https://pubmed.ncbi.nlm.nih.gov/32772069
43. Yaqoob H, Greenberg D, Hwang F, Lee C, Vernik D, Manglani R, et al.
Comparison of pulse-dose and high-dose corticosteroids with no
corticosteroid treatment for COVID-19 pneumonia in the intensive care
unit. J Med Virol. 2022 Jan;94(1):349–56.
44. Ho KS, Narasimhan B, Difabrizio L, Rogers L, Bose S, Li L, et al.
Impact of corticosteroids in hospitalised COVID-19 patients. BMJ open
Respir Res. 2021 Apr;8(1).
45. Fadel R, Morrison AR, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, et
al. Early Short-Course Corticosteroids in Hospitalized Patients With
COVID-19. Clin Infect Dis [Internet]. 2020;71(16):2114–20.
Available from: https://pubmed.ncbi.nlm.nih.gov/32427279/
46. Majmundar M, Kansara T, Lenik JM, Park H, Ghosh K, Doshi R, et al.
Efficacy of corticosteroids in non-intensive care unit patients with
COVID-19 pneumonia from the New York Metropolitan region. PLoS One.
2020;15(9):e0238827.
47. Salton F, Confalonieri P, Umberto Meduri G, Santus P, Harari S,
Scala R, et al. Prolonged Low-Dose Methylprednisolone in Patients With
Severe COVID-19 Pneumonia. Open Forum Infect Dis [Internet].
2020;7(10). Available from: file:///pmc/articles/PMC7543560/
48. Albani F, Fusina F, Granato E, Capotosto C, Ceracchi C, Gargaruti R,
et al. Corticosteroid treatment has no effect on hospital mortality in
COVID-19 patients. Sci Rep [Internet]. 123AD;11:1015. Available
from: https://doi.org/10.1038/s41598-020-80654-x
49. Fusina F, Albani F, Granato E, Meloni A, Rozzini R, Sabatini T, et
al. Effect of Corticosteroids on Mortality in Hospitalized COVID-19
Patients Not Receiving Invasive Mechanical Ventilation. Clin Pharmacol
Ther | Vol [Internet]. 2021;109(6). Available from:
http://www.cpt-journal.com
50. Russo GID, Solimini A, Zuccalà P, Antonella Zingaropoli M, Carraro
A, Pasculli P, et al. Real-life use of tocilizumab with or without
corticosteroid in hospitalized patients with moderate-to-severe COVID-19
pneumonia: A retrospective cohort study. PLoS One [Internet]. 2021;
Available from: https://doi.org/10.1371/journal.pone.0257376
51. Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei
S, et al. Intravenous methylprednisolone pulse as a treatment for
hospitalised severe COVID-19 patients: results from a randomised
controlled clinical trial. Eur Respir J [Internet]. 2020;56(6).
Available from: https://pubmed.ncbi.nlm.nih.gov/32943404/
52. Jamaati H, Hashemian SMR, Farzanegan B, Malekmohammad M, Tabarsi P,
Marjani M, et al. No clinical benefit of high dose corticosteroid
administration in patients with COVID-19: A preliminary report of a
randomized clinical trial. Eur J Pharmacol [Internet]. 2021;897.
Available from: https://pubmed.ncbi.nlm.nih.gov/33607104/
53. Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi MJ, Khaloo V,
Shahriarirad R, et al. Methylprednisolone or dexamethasone, which one is
superior corticosteroid in the treatment of hospitalized COVID-19
patients: a triple-blinded randomized controlled trial. BMC Infect Dis
[Internet]. 2021; Available from:
https://doi.org/10.1186/s12879-021-06045-3
54. Gragueb-Chatti I, Lopez A, Hamidi D, Guervilly C, Loundou A, Daviet
F, et al. Impact of dexamethasone on the incidence of
ventilator-associated pneumonia and blood stream infections in COVID-19
patients requiring invasive mechanical ventilation: a multicenter
retrospective study. Ann Intensive Care [Internet]. 2021;11:87.
Available from: https://doi.org/10.1186/s13613-021-00876-8
55. Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo
GC, et al. Methylprednisolone as Adjunctive Therapy for Patients
Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A
Randomized, Double-blind, Phase IIb, Placebo-controlled Trial. Clin
Infect Dis [Internet]. 2021;72(9):E373–81. Available from:
https://pubmed.ncbi.nlm.nih.gov/32785710/
56. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC,
et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in
Patients With Moderate or Severe Acute Respiratory Distress Syndrome and
COVID-19: The CoDEX Randomized Clinical Trial. JAMA [Internet]. 2020
Oct 6;324(13):1307–16. Available from:
https://doi.org/10.1001/jama.2020.17021
57. Ikeda S, Misumi T, Izumi S, Sakamoto K, Nishimura N, Ro S, et al.
Corticosteroids for hospitalized patients with mild to critically-ill
COVID-19: a multicenter, retrospective, propensity score-matched study.
Masamichi Mineshita. 2021;14.
58. Batirel A, Demirhan R, Eser N, Körlü E, Tezcan ME. Pulse steroid
treatment for hospitalized adults with COVID-19. Turkish J Med Sci. 2021
Oct;51(5):2248–55.
59. Ramiro sofia, mostard R, magro-checa césar, van dongen christel,
dormans T, Buijs J, et al. Historically controlled comparison of
glucocorticoids with or without tocilizumab versus supportive care only
in patients with COVID-19-associated cytokine storm syndrome: results of
the CHIC study. Ann Rheum Dis [Internet]. 2020;79:1143–51.
Available from: http://dx.doi.org/10.1136/annrheumdis-2020-218479
60. Gallay L, Tran V-T, Perrodeau E, Vignier N, Mahevas M, Bisio F, et
al. Fourteen-day survival among older adults with severe infection with
severe acute respiratory syndrome coronavirus 2 treated with
corticosteroid: a cohort study. Clin Microbiol Infect [Internet].
2021;27:1145–50. Available from:
https://doi.org/10.1016/j.cmi.2021.03.021
61. Polak SB, Van Gool IC, Cohen D, von der Thüsen JH, van Paassen J. A
systematic review of pathological findings in COVID-19: a
pathophysiological timeline and possible mechanisms of disease
progression. Mod Pathol an Off J United States Can Acad Pathol Inc. 2020
Nov;33(11):2128–38.
62. Sterne JAC, Murthy S, Diaz J V, Slutsky AS, Villar J, Angus DC, et
al. Association Between Administration of Systemic Corticosteroids and
Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.
JAMA. 2020 Oct;324(13):1330–41.
63. Sarkar S, Khanna P, Soni KD. Are the steroids a blanket solution for
COVID-19? A systematic review and meta-analysis. J Med Virol. 2021
Mar;93(3):1538–47.
64. Yuan M, Xu X, Xia D, Tao Z, Yin W, Tan W, et al. Effects of
Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity
Score-Based Analysis. Shock. 2020 Nov;54(5):638–43.
65. Lu X, Chen T, Wang Y, Wang J, Yan F. Adjuvant corticosteroid therapy
for critically ill patients with COVID-19. Vol. 24, Critical care
(London, England). 2020. p. 241.
66. Ni Y-N, Chen G, Sun J, Liang B-M, Liang Z-A. The effect of
corticosteroids on mortality of patients with influenza pneumonia: a
systematic review and meta-analysis. Crit Care. 2019 Mar;23(1):99.
67. Lu S, Zhou Q, Huang L, Shi Q, Zhao S, Wang Z, et al. Effectiveness
and safety of glucocorticoids to treat COVID-19: a rapid review and
meta-analysis. Ann Transl Med. 2020 May;8(10):627.
68. Tlayjeh H, Mhish OH, Enani MA, Alruwaili A, Tleyjeh R, Thalib L, et
al. Association of corticosteroids use and outcomes in COVID-19
patients: A systematic review and meta-analysis. J Infect Public Health.
2020 Nov;13(11):1652–63.